1. All morphologic changes represent a dose-dependent effect in a “time-space window.” That is, first, below a lower-dose threshold of functional alterations, no morphologic lesions occur despite the patient’s apparent illness, and, second, there is a time delay between the occurrence of a functional disturbance and the development of morphologic changes (called morphogenesis). Space refers to the fact that morphologic lesions are most extensive at the site of “toxic impact” and become less severe (and possibly less typical) with increasing distance. This should be kept in mind when taking biopsies for pathologic evaluation. 2. Whatever the quality of injury, the living organism reacts with a limited number of patterns. There are variations to these patterns, which may provide us with clues to the etiology of the injury, but no entirely new reactions can be expected, even when a new pathologic agent (such as human immunodeficiency virus) arises. The following figures provide examples of the 5 reaction patterns in different tissues and organs. TABLE 1-1 BASIC TYPES OF B-CELL AND T-CELL IMMUNOREACTIONS* a. Direct destruction of target antigenic cells by binding of CTL, Fas-related induction of apoptosis, and/or release of perforin and granzymes b. T-cell cytokine response activation of macrophages: granulomatous (e.g., IFN-γ, TNF) reaction c. T-cell cytokine response activation of mast cells: basophil reaction (e.g., IL-3, IL-5) d. T-cell cytokine response: activation of vasoproliferative factors (e.g., IL-3, IL-8) *CTL indicates cytotoxic T lymphocytes; Fas, cellular apoptosis receptor; Ig, immunoglobulin; IL, interleukin; IFN, interferon; IR, immunoreaction; TNF, tumor necrosis factor.
General Reaction Patterns
General Reaction Patterns
Gell and Coombs Type
Alias
Mechanism
B-cell reactions
Type I IR
Allergic IR
Atopic IR
Anaphylactic IR
Cytophilic antibodies (e.g., IgE) bind to mast cells; antigen binding to these cell-bound antibodies causes mast cell degranulation with release of vasoactive mediators (e.g., histamine), which initiate the microvascular inflammatory response (thrombocytes and eosinophils cooperate).
Type II IR
Toxic or cytotoxic IR
Complement-binding antibodies (on antigen binding) activate complement cascade, members of which initiate inflammatory response by activating cell chemotaxis and phagocytosis, ultimately causing toxic cell and tissue damage.
Type III IR
Immunocomplex IR
Persistence of antigen-antibody complexes are recognized by the immune system as foreign and induce the production of secondary anticomplex antibodies (i.e., anti-antibodies, such as rheumatoid factor); these bind and activate complement and cause tissue lesion through complement components (see above).
T-cell reactions
Type IV IR
Cell-mediated IR
T-cell cytotoxic IR
CTL response
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree